- Home
- FWRG vs ARQT Comparison
FWRG vs ARQT Comparison
Compare FWRG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- ARQT
- Stock Information
- Founded
- FWRG 1983
- ARQT 2016
- Country
- FWRG United States
- ARQT United States
- Employees
- FWRG N/A
- ARQT N/A
- Industry
- FWRG Restaurants
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- ARQT Health Care
- Exchange
- FWRG Nasdaq
- ARQT Nasdaq
- Market Cap
- FWRG 1.2B
- ARQT 1.1B
- IPO Year
- FWRG 2021
- ARQT 2020
- Fundamental
- Price
- FWRG $21.20
- ARQT $13.12
- Analyst Decision
- FWRG Strong Buy
- ARQT Strong Buy
- Analyst Count
- FWRG 10
- ARQT 5
- Target Price
- FWRG $23.50
- ARQT $17.00
- AVG Volume (30 Days)
- FWRG 471.5K
- ARQT 1.9M
- Earning Date
- FWRG 03-04-2025
- ARQT 02-25-2025
- Dividend Yield
- FWRG N/A
- ARQT N/A
- EPS Growth
- FWRG N/A
- ARQT N/A
- EPS
- FWRG 0.33
- ARQT N/A
- Revenue
- FWRG $997,252,000.00
- ARQT $138,708,000.00
- Revenue This Year
- FWRG $16.09
- ARQT $215.24
- Revenue Next Year
- FWRG $15.65
- ARQT $53.63
- P/E Ratio
- FWRG $64.35
- ARQT N/A
- Revenue Growth
- FWRG 19.77
- ARQT 182.84
- 52 Week Low
- FWRG $12.90
- ARQT $5.38
- 52 Week High
- FWRG $25.98
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- FWRG 62.39
- ARQT 47.68
- Support Level
- FWRG $18.78
- ARQT $12.09
- Resistance Level
- FWRG $21.90
- ARQT $15.09
- Average True Range (ATR)
- FWRG 0.93
- ARQT 0.83
- MACD
- FWRG 0.22
- ARQT -0.13
- Stochastic Oscillator
- FWRG 78.26
- ARQT 39.67
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.